KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biocryst Pharmaceuticals (BCRX) Accumulated Expenses (2023 - 2025)

Biocryst Pharmaceuticals (BCRX) has disclosed Accumulated Expenses for 8 consecutive years, with $92.6 million as the latest value for Q1 2025.

  • For the quarter ending Q1 2025, Accumulated Expenses rose 16.89% year-over-year to $92.6 million, compared with a TTM value of $92.6 million through Mar 2025, up 16.89%, and an annual FY2024 reading of $113.3 million, up 10.12% over the prior year.
  • Accumulated Expenses was $92.6 million for Q1 2025 at Biocryst Pharmaceuticals, down from $113.3 million in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $113.3 million in Q4 2024 and bottomed at $75.2 million in Q1 2023.
  • Average Accumulated Expenses over 3 years is $90.0 million, with a median of $89.6 million recorded in 2024.
  • Peak annual rise in Accumulated Expenses hit 34.64% in 2024, while the deepest fall reached 5.37% in 2024.
  • Year by year, Accumulated Expenses stood at $102.9 million in 2023, then grew by 10.12% to $113.3 million in 2024, then decreased by 18.23% to $92.6 million in 2025.
  • Business Quant data shows Accumulated Expenses for BCRX at $92.6 million in Q1 2025, $113.3 million in Q4 2024, and $104.2 million in Q3 2024.